Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Celsion Corporation Issues Statement Regarding Misleading Blog Entry



     Celsion Corporation Issues Statement Regarding Misleading Blog Entry

PR Newswire

LAWRENCEVILLE, N.J., June 12, 2013

LAWRENCEVILLE, N.J., June 12, 2013 /PRNewswire/ -- Celsion Corporation
(NASDAQ: CLSN) today issued the following statement regarding a blog entry
posted by Alpha Exposure, Contributor, on Seeking Alpha.com:

"Statements made in Alpha Exposure's blog entry are misleading and require
clarification.  

As is common in the biotechnology and pharmaceutical industry, Celsion has
conducted a comprehensive post hoc analysis of the data from its Phase III
HEAT Study of ThermoDox® in hepatocellular carcinoma (HCC) with its key
principal investigators, data experts and liver cancer experts.  This analysis
followed the announcement on January 31, 2013, that ThermoDox® in combination
with radiofrequency ablation (RFA) did not meet the Study's primary endpoint. 
Emerging findings from the HEAT Study post hoc analysis, which has provided
important insights regarding the use of ThermoDox® in conjunction with RFA to
treat HCC, suggests that ThermoDox® markedly improves progression-free
survival (PFS) and overall survival (OS) in patients if their lesions undergo
RFA for 45 minutes or more.  These findings apply to HCC lesions from both
size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable
subgroup of approximately 300 patients.  In the patient subgroup treated in
the ThermoDox arm whose RFA procedure lasted longer than 45 minutes (63% of
single lesion patients), overall survival improved by 53% (Hazard Ratio of
0.65 and a P[value] = 0.105) when compared to the control arm of RFA treatment
only.  While the Hazard Ratio reported above should be viewed with caution
since the HEAT Study has not reached its median point for overall survival
analysis, there is a strong signal which our investigators and data experts
consider to be encouraging and sufficient to warrant additional clinical
investigation.  These data were presented at a recent medical meeting of
interventional oncology by two of Celsion's lead investigators.  Furthermore,
the detailed data has been submitted for peer review at upcoming international
meetings in liver oncology and interventional oncology.  HEAT Study
investigators have agreed to the submission of the HEAT Study results and the
post hoc data for peer review. 

Celsion is refining the appropriate theoretical models to establish
quantitative predictions for the influence of RFA heating time on local tissue
concentrations of ThermoDox®.  Empirical studies will then be used to verify
the model predictions using appropriate animal studies which are targeted for
completion over the summer.  Assuming that our hypothesis is supported by
non-clinical studies as well as continued follow-up of patients in the HEAT
Study to the overall survival endpoint, we will meet with the U.S. Food and
Drug Administration to discuss these findings.  We would plan to propose a
regulatory path forward which may include additional clinical studies based on
FDA's predictive enrichment guidance.  Furthermore, investigators in the HEAT
Study have expressed significant interest in participating in a follow-on
clinical trial."

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative
cancer drugs, including tumor-targeting treatments using focused heat energy
in combination with heat-activated liposomal drug technology.  Celsion has
research, license or commercialization agreements with leading institutions,
including the National Institutes of Health, Duke University Medical Center,
University of Hong Kong, the University of Pisa, the UCLA Department of
Medicine, the Kyungpook National University Hospital, the Beijing Cancer
Hospital and the University of Oxford.  For more information on Celsion, visit
our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this
release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995.  Readers are cautioned that such
forward-looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials; the significant expense, time, and risk of
failure of conducting clinical trials; HEAT Study data is subject to further
verification and review by the HEAT Study Data Management Committee; the need
for Celsion to evaluate its future development plans; termination of the
Technology Development Contract or collaboration between Celsion and HISUN at
any time; possible acquisitions or licenses of other technologies, assets or
businesses or the possible failure to make such acquisitions or licenses;
possible actions by customers, suppliers, competitors, regulatory authorities;
and other risks detailed from time to time in the Celsion 's periodic reports
and prospectuses filed with the Securities and Exchange Commission.  Celsion
assumes no obligation to update or supplement forward-looking statements that
become untrue because of subsequent events, new information or otherwise.

Investor Contact 
Jeffrey W. Church 
Senior Vice President – Corporate  
Strategy and Investor Relations 
609-482-2455 
jchurch@celsion.com

SOURCE Celsion Corporation

Website: http://www.celsion.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement